Information Provided By: 
Fly News Breaks for May 17, 2019
BLUE
May 17, 2019 | 06:57 EDT
JPMorgan analyst Cory Kasimov thinks investors should use times of share weakness to buy or add to longer-term positions in Bluebird Bio. With the stock off nearly 20% since early April, "this could be one of those times," Kasimov tells investors in a research note. He believes Bluebird has a relatively high likelihood of going four-for-four with its initial late-stage shots on goal. The analyst maintains an Overweight rating on the shares with a $195 price target.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
